Related by context. All words. (Click for frequent words.) 71 FOLOTYN 70 Marqibo 69 Azedra 69 tanespimycin 68 elotuzumab 68 HuMax CD4 68 pralatrexate 68 Dacogen injection 68 HGS ETR1 68 EOquin 67 picoplatin 67 Plicera 67 lintuzumab 66 alvespimycin 66 registrational trial 66 perifosine 66 glufosfamide 66 INCB# [002] 66 PXD# 66 Amigal 66 EOquin TM 66 ofatumumab 65 INCB# [001] 65 MGCD# [001] 65 BiTE antibody 65 Amrubicin 65 TELCYTA 65 valopicitabine 65 HspE7 65 Restanza 65 Phase 2b trial 65 belinostat 64 amrubicin 64 phase IIa clinical 64 XL# [003] 64 phase IIb clinical 64 sapacitabine 64 obatoclax 64 registrational 64 Sym# 64 AP# [003] 64 Genasense 64 Archexin 64 Aurexis 64 Phase Ib 64 tesetaxel 64 AQ4N 64 Phase Ib study 64 teduglutide 64 OncoVEX GM CSF 64 romidepsin 64 otelixizumab 63 L BLP# 63 relapsed multiple myeloma 63 celgosivir 63 Neuradiab 63 Ceflatonin 63 pomalidomide 63 forodesine 63 imetelstat 63 ruxolitinib 63 YONDELIS 63 Phase 2b clinical 63 BAY #-# 63 MOZOBIL 63 relapsed refractory 63 satraplatin 63 JAK inhibitor 63 TACI Ig 63 eniluracil 63 IMGN# 63 Blinatumomab 63 Perifosine 63 ganetespib 63 albinterferon alfa 2b 63 Stimuvax R 63 IRX 2 63 HuMax CD# 63 rALLy trial 63 HGS ETR2 63 vandetanib 63 Proxinium TM 63 mRCC 63 ixabepilone 63 enzastaurin 63 BRIM2 63 talactoferrin 63 Telintra 63 EndoTAG TM -1 62 eculizumab 62 Phase IIIb clinical 62 recurrent GBM 62 Clolar 62 cilengitide 62 Traficet EN 62 Annamycin 62 Phase 2b 62 SUTENT 62 eltrombopag 62 GRN#L 62 castration resistant prostate cancer 62 Zerenex 62 crizotinib PF # 62 phase IIb 62 dacetuzumab 62 Stimuvax 62 IMA# 62 axitinib 62 elacytarabine 62 Panzem R NCD 62 tamibarotene 62 PROMACTA 62 Virulizin ® 62 RG# [001] 62 Phase IIa trial 62 OvaRex ® MAb 62 lumiliximab 62 clofarabine 62 PF # [001] 62 Alpharadin 62 PROSTVAC TM 62 dose cohort 62 Phase #b/#a 62 ZEVALIN 62 ELACYT 62 dirucotide 62 XmAb# 62 APOPTONE 62 daclizumab 62 BCX# 62 ozarelix 62 custirsen 62 Phase Ib clinical 62 Phase 1b 62 Troxatyl 62 Plenaxis TM 61 atacicept 61 Phase IIb clinical 61 vidofludimus 61 torezolid phosphate 61 EFAPROXYN 61 Phase 2a trial 61 zanolimumab 61 phase IIb trial 61 ATL# [001] 61 OXi# 61 methylnaltrexone 61 CCX# 61 HuLuc# 61 ponatinib 61 tivozanib 61 rindopepimut 61 GALNS 61 Asentar 61 Alocrest 61 TRIOLEX 61 Diamyd ® 61 GAMMAGARD 61 Alzhemed TM 61 Phase IIa clinical 61 ambrisentan 61 CA4P 61 Cloretazine R VNP#M 61 neratinib 61 Tamibarotene 61 Atiprimod 61 HER2 positive metastatic breast 61 Pralatrexate 61 confirmatory Phase III 61 GSK# [001] 61 ISTODAX 61 TREANDA 61 mapatumumab 61 HuMax EGFr 61 CBLC# 61 velaglucerase alfa 61 Nuvion 61 DXL# 61 tesmilifene 61 rNAPc2 61 phase IIa 61 AEG# 61 ASA# 61 teriflunomide 61 randomized Phase 2b 61 CYT# 61 ataluren 61 Tovaxin 61 pertuzumab 61 CR# vcMMAE 61 Allovectin 7 61 vosaroxin 61 ularitide 61 bendamustine 61 nonclinical studies 61 REOLYSIN ® 61 PEG Interferon lambda 61 cetrorelix 60 Phase 2b study 60 pivotal Phase III 60 OHR/AVR# 60 PSMA ADC 60 vicriviroc 60 TYKERB 60 voreloxin 60 nitazoxanide 60 decitabine 60 brentuximab vedotin 60 pharmacokinetic PK study 60 rALLy 60 ASONEP 60 apremilast 60 Bezielle 60 EDEMA4 60 Androxal TM 60 OMAPRO 60 Tavocept 60 dose cohorts 60 NUVIGIL 60 Bortezomib 60 TELINTRA 60 LymphoStat B 60 Xanafide 60 ALN RSV# 60 rFIXFc 60 BiovaxID 60 sunitinib malate 60 galiximab 60 GATTEX 60 omacetaxine 60 ceftaroline 60 Azedra TM 60 follicular NHL 60 anticancer compound 60 TBC# 60 PS# [001] 60 Phase #/#a trial 60 Viramidine 60 Cotara 60 relapsed refractory multiple myeloma 60 Vidaza 60 myelofibrosis 60 dose escalation phase 60 iclaprim 60 PROVENGE 60 denufosol 60 placebo controlled Phase 60 Fodosine 60 PSN# [002] 60 brivaracetam 60 oral prodrug 60 farletuzumab 60 relapsed MM 60 pediatric acute lymphoblastic 60 Icatibant 60 Fibrillex TM 60 refractory acute myeloid 60 deforolimus 60 AEGR 60 PREOS R 60 Onco TCS 60 CoFactor 60 PEG SN# 60 Triolex 60 phase Ib 60 dose escalation trial 60 VELCADE 60 OncoVEX 60 Phase Ib II 60 refractory CLL 60 oral methylnaltrexone 60 Phase III randomized controlled 60 AeroLEF TM 60 BrachySil TM 60 maribavir 60 Corlux 59 panitumumab 59 Amplimexon 59 pradefovir 59 L MTP PE 59 recurrent glioma 59 MEK inhibitor RDEA# 59 RhuDex ® 59 cancer neuroendocrine tumor 59 UVIDEM 59 IL# PE#QQR 59 FOLOTYN ® 59 PRX# 59 mipomersen 59 dose escalation clinical 59 CD3 monoclonal antibody 59 cutaneous T cell 59 AVADO 59 histone deacetylase HDAC inhibitor 59 PLK1 SNALP 59 KRN# 59 Cetrorelix 59 Phase IIb trials 59 Phase IIb trial 59 cariprazine 59 Numax 59 liposomal formulation 59 refractory prostate cancer 59 Betaferon ® 59 castrate resistant prostate cancer 59 Cloretazine R 59 milatuzumab 59 PREOS 59 BEXXAR 59 Pimavanserin 59 Symadex 59 lorvotuzumab mertansine 59 Telaprevir 59 AZD# 59 elesclomol 59 RIGScan CR 59 MBP# [001] 59 Clolar ® 59 HCD# [002] 59 Evoltra ® 59 PEP# [003] 59 ILLUMINATE 59 Phase III clinical 59 Apoptone 59 KNS # 59 romiplostim 59 Phase 1b trial 59 NEUMUNE 59 Androxal 59 OvaRex R 59 Omacetaxine 59 SUCCEED trial 59 subcutaneous formulation 59 PANVAC VF 59 Phase Ia 59 Trofex 59 oral ridaforolimus 59 Insegia 59 BrachySil 59 Ceflatonin R 59 Cloretazine ® 59 PROVENGE sipuleucel T 59 BRIM3 59 receptor tyrosine kinase inhibitor 59 Ambrisentan 59 Prochymal 59 cell lymphoma CTCL 59 EDEMA3 59 epratuzumab 59 HRPC 59 lomitapide 59 LHRH antagonist 59 Phase 2a 59 davunetide 59 omacetaxine mepesuccinate 59 Tarceva TM 59 cannabinor 59 mg/m2 cohort 59 Leukine 59 alvimopan 59 Veronate 59 regorafenib 59 Azixa 59 T DM1 59 investigational monoclonal antibody 59 dosing cohort 59 CEQ# 59 leading oral taxane 59 veltuzumab 59 MGd 59 rilonacept 59 adecatumumab 59 BLA filing 59 darapladib 59 elvucitabine 59 HQK 59 ZACTIMA 59 Phenoptin 59 bafetinib 59 Phase III 59 randomized Phase III 59 goserelin 59 chronic lymphocytic leukemia CLL 59 compound INCB# 59 baminercept 59 bortezomib Velcade R 59 investigational drug 59 placebo controlled clinical 59 Aflibercept 59 Folotyn 59 SYMMETRY trial 59 MAGE A3 ASCI 59 JAK1 59 RSD# 58 azacitidine 58 metastatic renal cell carcinoma 58 radiation sensitizer 58 Phase 1b clinical 58 VELCADE melphalan 58 multiple myeloma MM 58 Mipomersen 58 velafermin 58 palonosetron 58 Dacogen 58 clinical pharmacology studies 58 StemEx R 58 anti leukemic 58 R#/MEM # 58 Phase IIb clinical trials 58 rALLy clinical trial 58 mertansine 58 CIMZIA TM 58 Phase IIb 58 ocrelizumab 58 ADXS# 58 trastuzumab DM1 T DM1 58 depsipeptide 58 Quinamed 58 mCRC patients 58 ADVEXIN 58 figitumumab 58 Phase 1a 58 MAXY G# 58 MyVax R 58 Nanobody 58 rituximab 58 Allovectin 7 ® 58 mCRC 58 Serdaxin 58 HCV SPRINT 58 SAR# [004] 58 Targretin 58 Chemophase 58 TOCOSOL Paclitaxel 58 GRN# 58 indolent NHL 58 lymphoma CTCL 58 pafuramidine 58 Ostarine 58 Virulizin R 58 investigational compound 58 Aptivus ® 58 previously untreated follicular 58 TORISEL 58 Elagolix 58 Clavis Pharma 58 IPX# 58 maximally tolerated dose 58 anticancer agent 58 relapsing remitting multiple sclerosis 58 tezampanel 58 AVN# [001] 58 TOLAMBA 58 linaclotide 58 ISIS # 58 varespladib 58 Cloretazine 58 ALN VSP 58 lapatinib Tykerb 58 Aplidin 58 riociguat 58 nimotuzumab 58 VEGF Trap 58 Phase 2a clinical 58 thymalfasin 58 assessing T DM1 58 virus HCV protease inhibitor 58 Liprostin 58 TNFerade 58 pharmacokinetic PK profile 58 multicenter Phase 58 FavId 58 metaglidasen 58 dose escalation Phase 58 investigational therapies 58 SNT MC# 58 NP2 Enkephalin 58 NEUVENGE 58 hematologic malignancies 58 laquinimod 58 palifosfamide 58 Velcade bortezomib 58 vorinostat 58 refractory Hodgkin lymphoma 58 GATTEX ® 58 DAVANAT 58 biologic therapy 58 EGFR inhibitors 58 LEUKINE 58 MYDICAR ® 58 ALN TTR# 58 Halaven 58 AZILECT ® 58 bapineuzumab 58 leukemia CLL 58 BENLYSTA ® 58 cancer immunotherapies 58 TMC# [002] 58 BiTE 58 Phase IIa trials 58 VAPRISOL 58 Cethrin 58 Panzem 58 dimebon 58 EVIZON 58 Phase III psoriasis 58 EndoTAG 58 #I TM# 58 Reolysin 58 fidaxomicin 58 fipamezole 58 Guanilib 58 CHOP chemotherapy 58 TASQ 58 MNTX 58 Desmoteplase 58 forodesine hydrochloride 58 Arranon 58 ALD# 58 blinded randomized placebo controlled 58 samalizumab 58 Taxotere R 58 sorafenib Nexavar 58 NPSP# 58 Onrigin 58 refractory multiple myeloma 58 Xcellerated T Cells 58 RSD# oral 58 GRNVAC1 58 Dasatinib 58 Treanda 58 davunetide intranasal AL 58 treatment naive genotype 58 oral deforolimus 58 bazedoxifene 58 hematological cancers 58 Trastuzumab 58 Phase IIB 58 MDV# 58 Laquinimod 58 RGB # 58 dose escalation 58 clinical trial 58 Daclizumab 57 INCB# [003] 57 Vectibix monotherapy 57 OPAXIO 57 Fludara 57 B CLL 57 PCK# 57 tafamidis 57 ProLindac 57 GAP #B# 57 low dose cytarabine 57 Acetavance 57 INTERCEPT platelets 57 Genasense ® 57 sipuleucel T 57 gefitinib Iressa 57 Onalta 57 favorable pharmacokinetic profile 57 cell malignancies 57 AMR# 57 vilazodone 57 RLY# 57 randomized Phase 57 Ceplene 57 Alemtuzumab 57 phase 2a 57 Defibrotide 57 urocortin 2 57 gemcitabine Gemzar ® 57 TroVax 57 vascular disrupting agent 57 preclinically 57 pharmacokinetic PK 57 Nexavar ® 57 resminostat 57 non metastatic osteosarcoma 57 PNP inhibitor 57 SparVax TM 57 IDX# 57 C1 INH 57 randomized multicenter Phase III 57 Exherin TM 57 BLA submission 57 NXL# 57 LEP ETU 57 Octreolin 57 Aplidin R 57 monotherapy 57 iniparib 57 Voreloxin 57 RSR# 57 metastatic hormone refractory 57 AEZS 57 perifosine KRX 57 Neuvenge 57 trabedersen 57 VPRIV 57 PREZISTA r 57 BNC# 57 hematological malignancies 57 ProSavin 57 Rescula 57 L Annamycin 57 aclidinium 57 Omapro 57 recurrent glioblastoma multiforme 57 canakinumab 57 vernakalant 57 rBChE 57 abiraterone acetate 57 CBLB# 57 huC# DM4 57 Bicifadine 57 autologous cellular immunotherapy 57 ZYBRESTAT 57 docetaxel chemotherapy 57 MabCampath 57 BZL# 57 metastatic CRC 57 Rituximab 57 HDAC Inhibitor 57 leukemia AML 57 selective androgen receptor modulator 57 PROSTVAC VF 57 bicifadine 57 Cutaneous T 57 nilotinib 57 Campath 57 MIRCERA 57 PEG PAL 57 talabostat 57 PRTX 57 bosentan 57 TEMODAL 57 Phase IIb III 57 ZYBRESTAT fosbretabulin 57 telaprevir 57 prGCD 57 FTY# 57 Vandetanib 57 CYC# 57 Actilon 57 refractory metastatic colorectal cancer 57 Personalized Immunotherapy 57 AGGRASTAT ® 57 Fibrillex 57 nab paclitaxel 57 LAF# 57 SCH # 57 dosing cohorts 57 visilizumab 57 Exelixis XL# 57 Phase III trials 57 PI3K/Akt pathway inhibitor 57 Allovectin 7 R 57 Genz # 57 hA# 57 BIBW 57 ALKS 57 Amitiza 57 Phase III clinical trials 57 mg kg dose 57 eliglustat tartrate 57 AMD# [003] 57 BioNumerik 57 Ozarelix 57 CD# antibody [001] 57 Pirfenidone 57 ATL/TV# 57 Tanespimycin 57 metastatic castrate resistant 57 SPRYCEL ® 57 sorafenib tablets 57 ONTAK 57 RDEA# 57 pazopanib 57 PD LID 57 motesanib 57 cell lymphomas 57 Carfilzomib 57 heavily pretreated 57 PLX# 57 Revimmune 57 tremelimumab 57 Diamyd R 57 CTAP# Capsules 57 refractory chronic lymphocytic 57 Zenvia Phase III 57 Zolinza 57 dexanabinol 57 Prodarsan 57 Civacir 57 voclosporin 57 Randomized Phase 57 metastatic castration resistant 57 PRT# 57 Romidepsin 57 lupus nephritis 57 seliciclib 57 dirucotide MBP# 57 tramiprosate Alzhemed TM 57 UPLYSO 57 vinorelbine 57 bardoxolone 57 integrase inhibitor 57 Phase #b/#a clinical 57 Benlysta belimumab 57 NEBIDO 57 TLK# 57 RRMS patients 57 phase III ACCLAIM 57 ReN# 57 novel VDA molecule 57 natalizumab 57 Hepatocellular Carcinoma HCC 57 Phenserine 57 advanced carcinoid 57 pharmacodynamic PD 57 ridaforolimus 57 Zybrestat 57 miglustat 57 tipranavir r 57 Lu AA# 57 sunitinib 57 aflibercept 57 Hsp# inhibitor 57 Phase #/#a 57 Urocidin 57 CRLX# 57 Taxotere ® 57 secondary efficacy endpoints 57 Glufosfamide 57 zalutumumab 57 bortezomib 57 Telcyta 57 GLP toxicology studies 57 ALN TTR 57 Dextofisopam 57 GED aPC 57 Mylotarg 57 DR Cysteamine 57 ThermoDox ® 57 mifamurtide 57 Pertuzumab 57 efalizumab 57 TRISENOX 57 pharmacodynamic effects 57 cangrelor 57 randomized controlled Phase 56 LymphoStat B belimumab 56 ToGA 56 ara C 56 CYT# potent vascular disrupting 56 rhThrombin 56 HCV protease inhibitor 56 ZOLINZA 56 viral kinetics 56 confirmatory Phase 3 56 zileuton 56 opioid induced bowel dysfunction 56 COPAXONE ® 56 tolevamer 56 myelodysplastic syndromes MDS 56 docetaxel Taxotere R 56 COMFORT II 56 Temsirolimus 56 rPA anthrax vaccine 56 DAVANAT R 56 elagolix 56 ONCONASE 56 ADVEXIN clinical 56 hepatitis C HCV 56 posaconazole 56 TH# [003] 56 Tyrima 56 rhIGFBP 3 56 eprotirome 56 chronic myeloid leukemia CML 56 targeting CD# 56 recurrent NSCLC 56 APTIVUS r 56 entinostat 56 PDE4 inhibitor 56 active comparator 56 Urocidin TM 56 Vectibix 56 relapsed SCLC 56 XL# SAR# 56 tipranavir 56 Junovan 56 relapsed refractory ALL 56 pharmacodynamic 56 ITAX 56 ongoing Phase 1b 56 pharmacokinetics PK 56 Zavesca R 56 IRESSA 56 carfilzomib 56 ustekinumab 56 dexpramipexole 56 vemurafenib 56 Nicole Onetto MD 56 Tarvacin 56 peginesatide 56 chronic myelogenous leukemia CML 56 Degarelix 56 Stedivaze 56 Torisel 56 VitiGam 56 MultiStem 56 TroVax ® 56 APTIVUS 56 LEVADEX 56 romidepsin novel 56 GFT# 56 lixisenatide 56 SinuNase TM 56 Ophena TM 56 Tarvacin TM 56 DU #b 56 Locteron 56 ascending dose 56 metastatic HRPC 56 refractory indolent non 56 Bronchitol 56 personalized immunotherapy 56 TG# [003] 56 Altastaph 56 mGluR5 NAM 56 temsirolimus 56 DOS# 56 KRAS status 56 Ceplene/IL-2 56 cabazitaxel 56 omecamtiv mecarbil 56 DermaVir Patch 56 antiangiogenic therapy 56 Toraymyxin TM 56 Pradefovir 56 trastuzumab emtansine T DM1 56 LibiGel Phase III 56 anti EGFR antibody 56 ApoB SNALP 56 Saforis 56 abiraterone 56 refractory gout 56 tyrosine kinase inhibitor 56 APPRAISE 56 tosedostat 56 ACZ# 56 Phase 1a clinical 56 Dalbavancin 56 NGX# 56 tasocitinib 56 Rituxan 56 INT# [002] 56 SILENOR TM 56 ancrod 56 KIACTA ™ 56 docetaxel Taxotere ® 56 unique alkylating agent 56 ADAGIO study 56 Specifid 56 refractory cutaneous T 56 BAL# [002] 56 Phase IIIb 56 JAK inhibitors 56 ANA# 56 BR.# 56 PLX cells 56 MLN# 56 satraplatin Phase 56 Campath alemtuzumab 56 Cell Lymphoma 56 Jevtana 56 relapsed leukemia 56 Vernakalant 56 budesonide foam 56 Oncophage 56 ORENCIA R 56 cell chronic lymphocytic 56 iloperidone 56 CLL8 56 Vitaxin 56 MEND CABG 56 ACAPODENE 56 SEPET TM 56 relapsed MCL 56 Cinryze ™ 56 VNP#M 56 MAP# 56 Canvaxin TM 56 vismodegib 56 relapsed AML 56 ELND# 56 LE DT 56 Pivotal Phase 56 refractory AML 56 Vectibix panitumumab 56 IMC #B 56 Vacc 4x 56 Neulasta ® 56 DP b# 56 Neurodex 56 ANTEGREN 56 Denosumab 56 ONCONASE R 56 ThGRF 56 telaprevir dosed 56 THALOMID 56 OMP #M# 56 orally bioavailable 56 PRECISE trial 56 indibulin 56 optimal dosing regimens 56 diabetic neuropathic pain 56 Genasense R 56 Solazed 56 Cladribine Tablets 56 oritavancin 56 IIa trial 56 ICA # 56 ostarine 56 ARIKACE 56 brentuximab vedotin SGN 56 relapsing remitting MS RRMS 56 PrevOnco 56 orBec 56 randomized Phase IIb 56 TPI ASM8 56 Trofex TM 56 PTK ZK 56 Onconase 56 Kuvan 56 imatinib Gleevec ® 56 Fx #A 56 solid tumors 56 evaluable patients 56 oral FTY# 56 leukemia ALL 56 TG# [001] 56 apaziquone 56 Prestara 56 Evoltra 56 bortezomib Velcade 56 IMC A# 56 Androxal ® 56 refractory APL 56 Gleevec resistant 56 selective modulator 56 Ocrelizumab 56 Vicinium TM 56 Vilazodone 56 humanized anti 56 Hedgehog Pathway Inhibitor 56 bosutinib 56 SPRYCEL 56 pivotal Phase 56 dose escalation study 56 adult chronic ITP 56 proteasome inhibitor bortezomib 56 ruboxistaurin 56 oral Xeloda 56 glatiramer acetate 56 AVASTIN 56 TYZEKA 56 GSK # 56 MAXY alpha 56 prostate cancer CRPC 56 multicentre randomized 56 IAP inhibitor 56 dasatinib 56 Theratope 56 MEK inhibitor 56 randomized discontinuation trial 56 epothilone 56 Synavive 56 HGS# 56 RITUXAN 56 subcutaneous PRO 56 gefitinib 56 MERLIN TIMI 56 Catena ® 56 AGILECT R 56 angiographic outcomes 56 generation purine nucleoside 56 StemEx 56 inhibitor RG# 56 pitavastatin 56 Hedgehog antagonist 56 cabozantinib 56 Prostate AdenoCarcinoma Treatment 56 lesinurad 56 myelodysplastic syndrome MDS 56 tecarfarin 56 systemic anaplastic large